The 2019 coronavirus: Learning curves, lessons, and the weakest link.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Allosteric Interactions of Flavonoids with ACE2 and Potential Implications for COVID-19: Computational Insights, Metabolic and Mitochondrial Effects of Rutin in A549 Cells.Cell biochemistry and biophysics · 2026
   Article
2. Epidemiology, clinical characteristics and treatment of SARS-CoV-2 infection in children: A narrative review.International journal of clinical practice · 2021
   Review
3. The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy.International journal of cardiology · 2021
   Observational
4. Telemedicine and the 2019 coronavirus (SARS-CoV-2).International journal of clinical practice · 2020
   Article
5. Managing Biorisk Linked to Rapidly Expanding SARS-CoV-2 Research.Applied biosafety : journal of the American Biological Safety Association · 2020
   Article
6. COVID-19 and rationally layered social distancing.International journal of clinical practice · 2020
   Article
7. Where are we now with COVID-19?International journal of clinical practice · 2020
   Article
8. COVID-19: Social distancing, ACE 2 receptors, protease inhibitors and beyond?International journal of clinical practice · 2020
   Article
9. The 2019 coronavirus: Learning curves, lessons, and the weakest link.International journal of clinical practice · 2020
   Article
10. [Analysis of variation and evolution of SARS-CoV-2 genome].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020
    Article
11. Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis.Infection and drug resistance · 2020
    Article
12. Imported Infections in Rural Mid-West United States - A Report from a Tertiary Care Center.Missouri medicine
    Article
13. SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus.Travel medicine and infectious disease
    Review

Corrections and comments

• Commented on by
  Where are we now with COVID-19?2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.